Audrey Thurm1, Colby Chlebowski1, Lisa Joseph1, Cristan Farmer1, Dee Adedipe1, Madison Weiss1, Edythe Wiggs2, Nicole Farhat3, Simona Bianconi3, Elizabeth Berry-Kravis4, Forbes D Porter3. 1. Neurodevelopmental and Behavioral Phenotyping Service, National Institute of Mental Health, NIH, DHHS, Bethesda, MD. 2. National Human Genome Research Institute, National Institute of Mental Health, NIH, DHHS, Bethesda, MD. 3. Division of Translational Medicine, Eunice Kennedy Shriver National Institute of Child Health and Human Development, NIH, DHHS, Bethesda, MD. 4. Departments of Pediatrics, Neurological Sciences, and Biochemistry, Rush University Medical Center, Chicago, IL.
Abstract
OBJECTIVE: Niemann-Pick disease type C1 (NPC1) is a lysosomal storage disease characterized by progressive neurodegeneration, with the age of diagnosis ranging from the prenatal period through adulthood. Although neurological symptoms usually precede genetic diagnosis, they do not necessarily prompt diagnosis in the early years. Few prospective data are available to describe neurological onset, including neurodevelopmental delays, in children with NPC1. This dearth of information hinders the planning and implementation of adequate monitoring and treatment for the neurodevelopmental sequelae of NPC1. METHOD: Twenty-nine infants, toddlers, and preschoolers younger than 6 years participated in a natural history study and were administered neurodevelopmental assessments using instruments commonly used for early intervention screening in the community. RESULTS: Twenty-two of 29 participants met the criteria for a significant delay of at least 1.5 SDs below the mean in at least one domain of development; the youngest children often met these criteria for a significant delay based on motor delays, but cognitive and language delays were also common. However, only 11 of the 22 participants were reported to receive early intervention services before study entry. CONCLUSION: Although neurological symptoms may not prompt the genetic diagnosis of NPC1, the current findings support the use of a multimethod approach to repeated assessments for young children with the diagnosis because of the frequency of developmental delays or decline in multiple domains. The diagnosis of NPC1 alone should qualify children for evaluation for early intervention services and consideration of investigational therapeutic interventions.
OBJECTIVE: Niemann-Pick disease type C1 (NPC1) is a lysosomal storage disease characterized by progressive neurodegeneration, with the age of diagnosis ranging from the prenatal period through adulthood. Although neurological symptoms usually precede genetic diagnosis, they do not necessarily prompt diagnosis in the early years. Few prospective data are available to describe neurological onset, including neurodevelopmental delays, in children with NPC1. This dearth of information hinders the planning and implementation of adequate monitoring and treatment for the neurodevelopmental sequelae of NPC1. METHOD: Twenty-nine infants, toddlers, and preschoolers younger than 6 years participated in a natural history study and were administered neurodevelopmental assessments using instruments commonly used for early intervention screening in the community. RESULTS: Twenty-two of 29 participants met the criteria for a significant delay of at least 1.5 SDs below the mean in at least one domain of development; the youngest children often met these criteria for a significant delay based on motor delays, but cognitive and language delays were also common. However, only 11 of the 22 participants were reported to receive early intervention services before study entry. CONCLUSION: Although neurological symptoms may not prompt the genetic diagnosis of NPC1, the current findings support the use of a multimethod approach to repeated assessments for young children with the diagnosis because of the frequency of developmental delays or decline in multiple domains. The diagnosis of NPC1 alone should qualify children for evaluation for early intervention services and consideration of investigational therapeutic interventions.
Authors: Nicole M Yanjanin; Jorge I Vélez; Andrea Gropman; Kelly King; Simona E Bianconi; Sandra K Conley; Carmen C Brewer; Beth Solomon; William J Pavan; Mauricio Arcos-Burgos; Marc C Patterson; Forbes D Porter Journal: Am J Med Genet B Neuropsychiatr Genet Date: 2010-01-05 Impact factor: 3.568
Authors: Christian J Hendriksz; Mathieu Anheim; Peter Bauer; Olivier Bonnot; Anupam Chakrapani; Jean-Christophe Corvol; Tom J de Koning; Anna Degtyareva; Carlo Dionisi-Vici; Sarah Doss; Thomas Duning; Paola Giunti; Rosa Iodice; Tracy Johnston; Dierdre Kelly; Hans-Hermann Klünemann; Stefan Lorenzl; Alessandro Padovani; Miguel Pocovi; Matthis Synofzik; Alta Terblanche; Florian Then Bergh; Meral Topçu; Christine Tranchant; Mark Walterfang; Christian Velten; Stefan A Kolb Journal: Curr Med Res Opin Date: 2017-03-02 Impact factor: 2.580
Authors: Elizabeth Berry-Kravis; Jamie Chin; Anne Hoffmann; Amy Winston; Robin Stoner; Lisa LaGorio; Katherine Friedmann; Mariana Hernandez; Daniel S Ory; Forbes D Porter; Joan A O'Keefe Journal: Pediatr Neurol Date: 2018-01-08 Impact factor: 3.372
Authors: Daniel S Ory; Elizabeth A Ottinger; Nicole Yanjanin Farhat; Kelly A King; Xuntian Jiang; Lisa Weissfeld; Elizabeth Berry-Kravis; Cristin D Davidson; Simona Bianconi; Lee Ann Keener; Ravichandran Rao; Ariane Soldatos; Rohini Sidhu; Kimberly A Walters; Xin Xu; Audrey Thurm; Beth Solomon; William J Pavan; Bernardus N Machielse; Mark Kao; Steven A Silber; John C McKew; Carmen C Brewer; Charles H Vite; Steven U Walkley; Christopher P Austin; Forbes D Porter Journal: Lancet Date: 2017-08-10 Impact factor: 202.731
Authors: Mercedes Pineda; Eugen Mengel; Helena Jahnová; Bénédicte Héron; Jackie Imrie; Charles M Lourenço; Vanessa van der Linden; Parvaneh Karimzadeh; Vassili Valayannopoulos; Pavel Jesina; Juan V Torres; Stefan A Kolb Journal: BMC Pediatr Date: 2016-07-22 Impact factor: 2.125
Authors: Beth I Solomon; Andrea M Muñoz; Ninet Sinaii; Nicole M Farhat; Andrew C Smith; Simona Bianconi; An Dang Do; Michael C Backman; Leonza Machielse; Forbes D Porter Journal: Orphanet J Rare Dis Date: 2022-09-05 Impact factor: 4.303